Angebote zu "Clinical" (10 Treffer)

Kategorien

Shops

Responses of CLL cells to purine analogs with c...
21,99 € *
ggf. zzgl. Versand

Our findings demonstrate the need of ex vivo chronic lymphocytic leukemia cell (CLL) treatment before the application of drugs to select the most efficient manner of the patient s therapy. The obtained results confirm the link between the outcomes of the research done under ex vivo and in vivo conditions and underline the usefulness of ex vivo studies in the individual choice of CLL treatment. Our observations provide a base for further studies on the relationship between the in vivo clinical responses of patients and ex vivo pro-apoptotic activity, and the cytotoxicity of drugs against leukemic cells. Their validation by a study comprising a much larger group of patients is needed.

Anbieter: Dodax
Stand: 29.09.2020
Zum Angebot
TGN1412
34,00 € *
ggf. zzgl. Versand

High Quality Content by WIKIPEDIA articles! High Quality Content by WIKIPEDIA articles! TGN1412 (also known as CD28-SuperMAB) is the working name of an immunomodulatory drug which was withdrawn from development. Originally intended for the treatment of B cell chronic lymphocytic leukemia (B-CLL) and rheumatoid arthritis, it is a humanised monoclonal antibody that not only binds to, but is a strong agonist for, the CD28 receptor of the immune system's T cells. In its first human clinical trials in March 2006, it caused catastrophic systemic organ failure in the subjects, despite being administered at a supposed sub-clinical dose of 0.1 mg per kg, some 500 times lower than the dose found safe in animals. Six volunteers were hospitalized on 13 March 2006, at least four of these suffering from multiple organ dysfunction, and one trial volunteer is said to show signs of developing cancer.

Anbieter: Dodax
Stand: 29.09.2020
Zum Angebot
Chronic Lymphocytic Leukemia: from A to Z
39,90 € *
ggf. zzgl. Versand

Chronic lymphocytic leukemia is the most common leukemia affecting mainly elderly individuals and follows an extremely variable course, with survival ranging from months to decades. Several characteristics of CLL facilitate basic and translational research including the high population prevalence, the easily obtainable malignant cells through venous phlebotomy, the asymptomatic phase in most patients that allows for longitudinal evaluation, and the relatively long disease-specific survival. Consensus guidelines for treatment of patients with CLL have been proposed by the ESMO Clinical Practice Guidelines, and recently recommended that the current use of prognostic tools for patients with newly diagnosed CLL should include staging (Rai or Binet), lymphocyte doubling time (LDT), Beta-2 microglobulin (beta2M), CD38 and ZAP-70 markers, CLL-relevant fluorescence in situ hybridization (FISH) panel, and, if available, IgVH gene mutation status.

Anbieter: Dodax
Stand: 29.09.2020
Zum Angebot
Advances in Chronic Lymphocytic Leukemia
181,89 € *
ggf. zzgl. Versand

Chronic lymphocytic leukemia (CLL) is the most common leukemia in the Western world. CLL has a highly varied clinical course. While advances in CLL therapy are noted, many patients still succumb to this illness. Like most progress in medicine, solid advances in the diagnosis, prognosis and treatment of CLL are rooted in an in-depth understanding of the basic and translational biology of CLL. In this book, CLL experts have contributed state-of-the-art summaries of various important aspects of CLL biology and have discussed the translational implication of such findings. This book, which is directed at physicians and researchers alike, aims to educate broadly and deeply. Intentionally, the many aspects and nuances of CLL clinical care that can only really be appreciated through direct patient care are not covered here, but instead, the book presents basic aspects of CLL that underlie many of the contemporary decisions that are made in CLL research and clinical settings.We hope that this book will critically inform the community and stimulate interest in CLL, which will ultimately translate into better CLL research, prognostication and therapy, with the end goal of providing a better outlook for patients afflicted with this common leukemia.

Anbieter: Dodax
Stand: 29.09.2020
Zum Angebot
Chronic Lymphocytic Leukemia
79,45 € *
ggf. zzgl. Versand

This book summarizes current knowledge on chronic lymphocytic leukemia (CLL), taking into account the most recent research. All aspects are considered, including pathophysiology, clinical presentation, diagnosis, prognosis, treatment, follow-up, and complications and their management. Readers will find important information on the various prognostic markers as well as practical guidance on the use of different diagnostic procedures. A key focus of the book is the changing treatment paradigm in CLL as progress in understanding of pathogenesis and pathophysiology leads to the identification of new potential therapeutic targets. General treatment concepts are clearly described, and it is explained how choice of treatment for CLL depends on stage, age, and performance status as well as specific genetic aberrations. In addition, frontline therapeutic strategies for disease relapse, including allogeneic stem cell transplantation, are reported. Looking beyond CLL, the diagnosis and therapy of T-cell prolymphocytic leukemia and T-cell large granular lymphocyte leukemia, two rare CLL-related entities, are addressed.  

Anbieter: Dodax
Stand: 29.09.2020
Zum Angebot
Chronic Lymphocytic Leukemia
250,90 CHF *
ggf. zzgl. Versand

Chronic lymphocytic leukaemia (CLL) is the most common leukaemia in the Western world. It is also the prototype of B-cell chronic lymphoid malignancies and of their ramifications within the fields of hematology, immunology and oncology. For a long time the Cinderella of lymphoid malignancies CLL has now become the focus of major interest and an increasing number of investigators from different areas, including genetics, molecular biology, basic and applied immunology are becoming actively engaged in the investigation of CLL. Clinicians are considering CLL as a very interesting target of many projects which aim at translating the new and exciting developments of basic science into effective new approaches to the patient. TOC:B Cell Development and Its Deregulation to Transformed States at the Pre B Cell Receptor - Expressing Pre BII Cell Stage.- Gene Expression Patterns in Human and Mouse B Cell Development.- New Insights Into the Phenotype and Cell Derivation of B-Cell Chronic Lymphocytic Leukemia.- Chronic Lymphocytic Leukemia: Molecular Genetics and Animal Models.- What Do Somatic Hypermutation and Classic Switch Recombination Teach Us About Chronic Lymphocytic Leukemia Pathogenesis.- Chronic Lymphocytic Leukemia: A Review of the Immunoarchitecture.- Clinical and Laboratory Parameters That Define B-CLL Subgroups of Clinical Relevance.- Differential Effects on CLL Cell Survival Exerted by Different Microenvironmental Elements.- Genotypic Prognostic Markers.- Chronic Lymphocytic Leukemia: Clinical Translations of Biological Features.- Subject Index.

Anbieter: Orell Fuessli CH
Stand: 29.09.2020
Zum Angebot
Responses of CLL cells to purine analogs with c...
21,99 € *
ggf. zzgl. Versand

Our findings demonstrate the need of ex vivo chronic lymphocytic leukemia cell (CLL) treatment before the application of drugs to select the most efficient manner of the patient's therapy. The obtained results confirm the link between the outcomes of the research done under ex vivo and in vivo conditions and underline the usefulness of ex vivo studies in the individual choice of CLL treatment. Our observations provide a base for further studies on the relationship between the in vivo clinical responses of patients and ex vivo pro-apoptotic activity, and the cytotoxicity of drugs against leukemic cells. Their validation by a study comprising a much larger group of patients is needed.

Anbieter: Thalia AT
Stand: 29.09.2020
Zum Angebot
Chronic Lymphocytic Leukemia
220,00 € *
ggf. zzgl. Versand

Chronic lymphocytic leukaemia (CLL) is the most common leukaemia in the Western world. It is also the prototype of B-cell chronic lymphoid malignancies and of their ramifications within the fields of hematology, immunology and oncology. For a long time the Cinderella of lymphoid malignancies CLL has now become the focus of major interest and an increasing number of investigators from different areas, including genetics, molecular biology, basic and applied immunology are becoming actively engaged in the investigation of CLL. Clinicians are considering CLL as a very interesting target of many projects which aim at translating the new and exciting developments of basic science into effective new approaches to the patient. TOC:B Cell Development and Its Deregulation to Transformed States at the Pre B Cell Receptor - Expressing Pre BII Cell Stage.- Gene Expression Patterns in Human and Mouse B Cell Development.- New Insights Into the Phenotype and Cell Derivation of B-Cell Chronic Lymphocytic Leukemia.- Chronic Lymphocytic Leukemia: Molecular Genetics and Animal Models.- What Do Somatic Hypermutation and Classic Switch Recombination Teach Us About Chronic Lymphocytic Leukemia Pathogenesis.- Chronic Lymphocytic Leukemia: A Review of the Immunoarchitecture.- Clinical and Laboratory Parameters That Define B-CLL Subgroups of Clinical Relevance.- Differential Effects on CLL Cell Survival Exerted by Different Microenvironmental Elements.- Genotypic Prognostic Markers.- Chronic Lymphocytic Leukemia: Clinical Translations of Biological Features.- Subject Index.

Anbieter: Thalia AT
Stand: 29.09.2020
Zum Angebot
21st Century Adult Cancer Sourcebook: Chronic L...
13,40 € *
ggf. zzgl. Versand

21st Century Adult Cancer Sourcebook: Chronic Lymphocytic Leukemia (CLL) - Clinical Data for Patients, Families, and Physicians

Anbieter: Thalia AT
Stand: 29.09.2020
Zum Angebot